CSA Medical is a Lexington, Massachusetts medical device company that develops spray cryotherapy technology for the lungs. Its flagship RejuvenAir System delivers a metered dose of -196°C liquid nitrogen through a bronchoscope to destroy the damaged, mucus-producing cells that drive chronic bronchitis in COPD patients, while preserving the underlying tissue matrix so healthy airway cells can regrow. Backed by roughly $161M in total funding including a $53M Series D in 2024, the company submitted its FDA PMA in January 2026 following a successful pivotal SPRAY-CB trial.
Mosanna Therapeutics is a clinical-stage biotech developing MOS118, a bedtime nasal spray for obstructive sleep apnea (OSA). Rather than mechanically forcing the airway open like CPAP, MOS118 is a small molecule pan-K+ channel inhibitor that reactivates the body's own negative pressure reflex - stimulating pressure-sensing nerves in the nasopharynx to increase upper airway muscle tone and reduce apnea episodes. Founded in 2022 and headquartered in Redwood City, California with an office in Basel, Switzerland, the company launched publicly in June 2025 with an $80 million Series A to advance MOS118 through Phase 2.
Noel Greenberger is the CEO of Nob Hill Therapeutics, an Albuquerque-based respiratory company building DryNeb, a dry powder nebulizer that pushes high therapeutic doses deep into the lungs regardless of a patient's breathing capacity. A Wharton MBA and Northwestern-trained industrial engineer, he spent years commercializing respiratory medicines at Sandoz, ran commercial strategy at Vertice Pharma, and consulted at McKinsey and ZS Associates before taking the helm of Nob Hill in 2022. Under his watch the company won a $1.73M HHS Phase II grant and closed a $3M Series A in 2024.
Theravance Biopharma is a South San Francisco biopharmaceutical company built around a focused respiratory franchise. Its flagship product, YUPELRI (revefenacin), is the first and only once-daily nebulized long-acting muscarinic antagonist approved in the U.S. for COPD maintenance, commercialized with partner Viatris. Spun out of Innoviva in 2014 and trading on Nasdaq as TBPH, the company combines a profitable marketed product with high-value royalty assets - including a now-monetized stake in GSK's TRELEGY - and runs a lean, capital-disciplined model rather than chasing scale.
Aluna is a San Francisco digital health company that turns daily breathing into data. Its FDA-cleared, palm-sized spirometer pairs with a gamified app and a clinician dashboard so people with asthma, COPD and cystic fibrosis - and their doctors - can track lung function (FEV1) at home and catch trouble before it becomes an emergency. Founded by three UC Berkeley alumni and originally named Knox Medical Diagnostics, Aluna raised about $27M total, including a $15.3M Series B in 2023, and was acquired by Huma in May 2025.
Nocion Therapeutics is a clinical-stage biopharmaceutical company in the Boston area developing a new class of small-molecule 'charged' sodium channel blockers - nocions - that selectively, locally, and durably silence overactive sensory neurons (nociceptors) without numbing everything else. Its lead candidate, taplucainium, is an inhaled powder aimed at refractory and unexplained chronic cough, with broader potential across itch, pain, and neurogenic inflammation. The science was born in the Harvard Medical School and Boston Children's Hospital labs of Bruce Bean and Clifford Woolf.